Which of the following statements regarding Atomoxetine is true?

Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily in the treatment of attention-deficit hyperactivity disorder (ADHD). The statement regarding the increased risk of cardiovascular events is true because Atomoxetine can lead to elevated blood pressure and heart rate, which are significant factors contributing to cardiovascular risks. Monitoring of cardiovascular status is recommended when initiating treatment, especially in patients with pre-existing conditions.

The other choices relate to aspects that don't align with Atomoxetine's primary indications or side effects. It is not mainly used for depressive disorders, nor is sedation a major side effect associated with it; in fact, some patients may experience sympathomimetic effects such as insomnia. While Atomoxetine may help some patients with anxiety due to its role in enhancing norepinephrine levels, it is not specifically indicated for treating anxiety symptoms. Therefore, the most accurate statement pertained to its cardiovascular risk profile, justifying why that choice stands out.